Media headlines about NovoCure Limited (NASDAQ:NVCR) have been trending somewhat positive this week, according to Accern. The research group identifies positive and negative news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NovoCure Limited earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 46.2284735952152 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:
- Analyzing ZIOPHARM Oncology (ZIOP) and NovoCure Limited (NVCR) (americanbankingnews.com)
- NovoCure Limited (NVCR) CEO Asaf Danziger Sells 35,500 Shares (americanbankingnews.com)
- NovoCure Limited (NVCR) CEO Asaf Danziger Sells 37,272 Shares (americanbankingnews.com)
- NovoCure Reaches Analyst Target Price (nasdaq.com)
- NovoCure Limited (NVCR) noted a price change of 0.25% and AmpliPhi Biosciences Corporation (APHB) closes with a … – Stocks Gallery (stocksgallery.com)
A number of research analysts recently issued reports on the stock. Zacks Investment Research cut shares of NovoCure Limited from a “buy” rating to a “hold” rating in a report on Tuesday, August 1st. BidaskClub lowered shares of NovoCure Limited from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Mizuho began coverage on shares of NovoCure Limited in a research note on Wednesday, September 6th. They issued a “buy” rating and a $25.00 price target on the stock. Deutsche Bank AG reaffirmed a “hold” rating and issued a $19.00 price target (up previously from $18.00) on shares of NovoCure Limited in a research note on Monday, July 17th. Finally, ValuEngine raised shares of NovoCure Limited from a “sell” rating to a “hold” rating in a research report on Saturday, June 3rd. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $20.00.
Shares of NovoCure Limited (NVCR) traded down 4.40% during trading on Friday, reaching $20.65. 1,138,966 shares of the company were exchanged. The firm’s 50 day moving average price is $19.67 and its 200 day moving average price is $14.42. The company’s market capitalization is $1.84 billion. NovoCure Limited has a one year low of $5.95 and a one year high of $22.30.
NovoCure Limited (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.01). NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. The company had revenue of $38.38 million for the quarter, compared to the consensus estimate of $42.20 million. Equities research analysts forecast that NovoCure Limited will post ($0.77) earnings per share for the current fiscal year.
In other news, major shareholder Pomona Capital Vii Fund Invest sold 1,072,532 shares of NovoCure Limited stock in a transaction on Monday, June 26th. The stock was sold at an average price of $17.35, for a total transaction of $18,608,430.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Asaf Danziger sold 35,500 shares of NovoCure Limited stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $22.01, for a total value of $781,355.00. Following the sale, the chief executive officer now owns 776,862 shares in the company, valued at $17,098,732.62. The disclosure for this sale can be found here. Insiders have sold a total of 1,948,353 shares of company stock worth $34,307,144 over the last quarter. Company insiders own 16.70% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “NovoCure Limited (NVCR) Receiving Somewhat Favorable News Coverage, Study Shows” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://transcriptdaily.com/2017/09/17/novocure-limited-nvcr-receiving-somewhat-favorable-news-coverage-study-shows.html.
NovoCure Limited Company Profile
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.